Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAmortizatization of IntangiblesCapital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Account PayablesChange in Account PayablesChange in Accured ExpensesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in InventoryChange in ReceivablesChange in ReceivablesChange in TaxesChange in TaxesDepreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and DepletionDepreciation and DepletionFree Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesNet Cash FlowNet Cash FlowNet IncomeShare-based CompensationShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Agios Pharmaceuticals (AGIO) Gains from Sales and Divestitures (2016)

Agios Pharmaceuticals (AGIO) has disclosed Gains from Sales and Divestitures for 5 consecutive years, with $7500.0 as the latest value for Q4 2016.

  • For Q4 2016, Gains from Sales and Divestitures fell 11.99% year-over-year to $7500.0; the TTM value through Dec 2016 reached $7500.0, down 11.99%, while the annual FY2016 figure was $7500.0, 11.99% down from the prior year.
  • Gains from Sales and Divestitures hit $7500.0 in Q4 2016 for Agios Pharmaceuticals, roughly flat from $7500.0 in the prior quarter.
  • Across five years, Gains from Sales and Divestitures topped out at $183713.0 in Q4 2012 and bottomed at $2841.0 in Q1 2015.
  • Average Gains from Sales and Divestitures over 5 years is $41905.1, with a median of $8522.0 recorded in 2015.
  • Year-over-year, Gains from Sales and Divestitures crashed 90.55% in 2014 and then soared 32.02% in 2016.
  • Agios Pharmaceuticals' Gains from Sales and Divestitures stood at $183713.0 in 2012, then fell by 25.56% to $136758.0 in 2013, then crashed by 89.2% to $14773.0 in 2014, then crashed by 42.31% to $8522.0 in 2015, then fell by 11.99% to $7500.0 in 2016.
  • According to Business Quant data, Gains from Sales and Divestitures over the past three periods came in at $7500.0, $7500.0, and $7500.0 for Q4 2016, Q3 2016, and Q2 2016 respectively.